Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 148

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 148
---
 including in connection with a business combination. A further negative consequence of our delisting from Nasdaq will result from the fact that the closing of the Business Combination is conditioned on the listing of the post -combinationcompany on Nasdaq. Although we believe that, after our securities are delisted from Nasdaq, we may still potentially be able to meet Nasdaq’s initial listing 50 requirements via the consummation of the Business Combination, there can be no guarantee that Nasdaq will approve such initial listing application, which may delay, or ultimately prevent the consummation of the proposed Business Combination. If, following the Business Combination, securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market, or if they change their recommendations regarding our securities adversely, then the price and trading volume of our securities could decline. The trading market for our Company Shares will be influenced by the research and reports that industry or securities analysts may publish about the us, our business, our market, or our competitors. If no securities or industry analysts commence to cover us, the trading price and volume of our securities would likely be negatively impacted. If any of the analysts who may cover us adversely change their recommendation regarding our securities, or provide more favorable relative recommendations about our competitors, the price of our securities would likely decline. If any analyst who may cover SPAC were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause the price of trading volume of our securities to decline. We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and the price of our ordinary shares. We have identified material weaknesses in our internal control over financial reporting in respect of OmnigenicsAI. Further, the management of APx has identified and reported material weaknesses (see “ — Risks Related to APx — APx has identified material weaknesses in its internal control over financial reporting. If APx is unable to remediate these material weaknesses or otherwise fail to maintain an effective system of internal controls, it may not be able to accurately or timely report its financial condition or results of operations, which may adversely affect its business and the price of its ordinary shares”). A material weakness is a deficiency, or a combination of deficiencies, in internal control over